Overview

Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial

Status:
Completed

Trial end date:
2012-04-01

Target enrollment:
0

Participant gender:
All

Summary

Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was also effective in preventing cardiovascular events. The purpose of this study is to investigate whether an angiotensin II receptor blocker, candesartan, is effective in reducing the incidence of cardiovascular events after drug-eluting stent implantation.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Kumamoto University

Collaborators:

Japan Heart Foundation
The 4C trial bureau

Treatments:

Candesartan
Candesartan cilexetil

Criteria

Inclusion Criteria:

- A. Patients with hypertension, systolic blood pressure (SBP) = or > 140 and/or
diastolic blood pressure (DBP) = or > 90

- B. Patients with symptomatic heart failure lasting at least for 4 weeks (NYHA class =
or > II), or those need continuous use of diuretics

- C. Patients underwent coronary angioplasty with drug-eluting stents

Eligible patients are those who meet (A or B) and C.

Exclusion Criteria:

- Severe renal or hepatic disease

- Candidates for coronary artery bypass grafting (CABG)

- Within 3 months after CABG

- Allergic history to candesartan

- Pregnant women